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ABSTRACT 
Huntington’s disease is an inherited intricate brain illness. It is a neurodegenerative, insidious disorder; the
onset of the disease is very late to diagnose. It is caused by an expanded CAG repeat in the Huntingtin
gene,  which  encodes  an  abnormally  long  polyglutamine  repeat  in  the  Huntingtin  protein.  Huntington’s
disease has served as a model for the study of other more common neurodegenerative disorders, such as
Alzheimer’s disease and Parkinson’s disease. Symptomatic treatment of Huntington’s disease involves use
of  Dopamine  antagonists,  presynaptic  dopamine  depleters,  Antidepressants,  Tranquillizers,Anxiolytic
Benzodiazepines, Anticonvulsants and Antibiotics. Several medications including baclofen,idebenone and
vitamin E, Zinc-finger nucleases (ZFNs) have been studied in clinical trials with limited samples. In the
present article, we have concentrated on clinical features, diagnosis, symptomatic approaches, symptomatic
treatment and other therapies involved in the management of Huntington’s disease. 
INTRODUCTION
Huntington’s disease (HD) is a neurodegenerativegenetic disorder that affects muscle coordination and leads
to cognitive decline and psychiatric problems. It typically becomes noticeable in mid-adult life. [1] HD is the
most common genetic cause of abnormal involuntary writhing movements called chorea, which is why the
disease used to be called Huntington’s chorea. [4]For many decades its name remained unchanged, until the
nineteen-eighties when, fully aware of the extensive non-motor symptoms and signs, the name was changed
to Huntington’s disease (HD). [2] In 1983, a linkage on chromosome 4 was established and in 1993 the gene
for HD was found. For the first time, actual pre-manifest diagnoses could be made and as more diseases
involving trinucleotide repeats of CAG were found, HD served as a model for many studies in medicine. CAG
(cytosine (C), adenine (A), and guanine (G)), is a trinucleotide, the building stone of DNA. CAG is the codon
for the amino acid glutamic. Finding the gene opened new research lines, new models and for the first time a
real rationale on the way to treat this devastating disease. Many symptomatic treatments are now available,
but there is a need for better, modifying drugs. [3] HD is named after George Huntington, the physician who
described it as hereditary chorea in 1872. [3, 4]
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Figure 1
3-dimensional (3D) view of HD affected nerve cell.
EPIDEMIOLOGY
HD affects males and females in relatively equal numbers. The disorder occurs in various geographic and
ethnic populations worldwide. The frequency of HD appears to vary among different populations, ranging
from an estimated 4 to 10 individuals in 10,000.[6]Huntington’s disease shows a stable prevalence in most
populations of white people of about 5-7 affected individuals per 100000. [7] Exceptions can be seen in areas
where the population can be traced back to a few founders, such as Tasmania and the area around Lake
Maracaibo in Venezuela. In Japan, prevalence of the disorder is 0.5 per 100 000, about 10% of that recorded
elsewhere,  and  the  rate  is  much  lower  in  most  of  Asia.  African  populations  show a  similarly  reduced
prevalence, although in areas where much intermarriage with white people takes place the frequency is
higher. [6, 7] Currently, the higher incidence of Huntington’s disease in white populations compared with
African or Asian people relates to the higher frequency of Huntingtin alleles with 28-35 CAG repeats in white
individuals. [8]
SIGNS AND SYMPTOMS
Huntington’s disease is a widely variable disorder,  even within the same family. The early symptoms of
Huntington’s disease generally include slight, uncontrollable muscular movements, Chorea, stumbling and
clumsiness,  lack  of  concentration,  lapses  of  short-term  memory,  depression,  and  changes  of  mood,
sometimes including aggressive or antisocial behavior. [2, 3]The rate of progression of Huntington’s disease
varies, but generally, it develops over 15-25 years. [5] Later in the illness, people may experience different
symptoms, which include involuntary movements, Difficulty in speech and swallowing, Weight loss as well as
emotional changes, resulting in: Stubbornness, Frustration, Mood swings, Depression.
Chorea (derived from the Greek word meaning to dance) is the most common movement disorder seen in
HD.  [4]  Chorea is  a  characteristic  feature of  HD and, until  recently;  the disorder  commonly was called
Huntington chorea. [9] Chorea, as defined by the World Federation of Neurology, is a state of excessive,
spontaneous movements, irregularly timed, randomly distributed, and abrupt which is evidently illustrated in
figure 2. Severity of chorea may vary from restlessness with mild intermittent exaggeration of gesture and
expression, fidgeting movements of the hands, and unstable dance like gait to a continuous flow of disabling
violent  movements.  Initially,  mild  chorea  may  pass  for  fidgetiness.  [2]  Severe  chorea  may  appear  as
uncontrollable flailing of the extremities (i.e., ballism), which interferes with function.
 
Figure 2
The figure displays characteristic choreic movements.
Cognitive decline is characteristic of  HD, but the rate of  progression among individual patients can vary
considerably. Dementia and the psychiatric  features of  HD are perhaps the earliest  and most  important
indicators  of  functional  impairment.  [4]The dementia  syndrome associated with  HD includes  early onset
behavioral changes, such as irritability, untidiness, and loss of interest. Slowing of cognition, impairment of
intellectual function, and memory disturbances are seen later. This pattern corresponds well to the syndrome
of sub cortical dementia, and it has been suggested to reflect dysfunction of frontal-sub cortical neuronal
circuitry.Early stages of HD are characterized by deficits in short-term memory, followed by motor dysfunction
and  a  variety  of  cognitive  changes  in  the  intermediate  stages  of  dementia.  [9]  These  deficits  include
diminished verbal fluency, problems with attention, executive function, visuospatial processing, and abstract
reasoning. [5] Language skills become affected in the final stages of the illness, resulting in a marked word-
retrieval deficit. The behavioral disorder of HD is represented most commonly by affective illness. Depression
is more prevalent, with a small percentage of patients experiencing episodic bouts of mania characteristic of
bipolar disorder. [4, 5] Patients with HD and persons at risk for HD may have an increased rate of suicide.
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Patients with HD also can develop psychosis, obsessive-compulsive symptoms, sexual and sleep disorders
and changes in personality. [9]
PATHOLOGENOIUS
The selective neuronal dysfunction and subsequent loss of neurons in the striatum, cerebral cortex, and other
parts of the brain can explain the clinical picture seen in cases of HD. Several mechanisms of neuronal cell
death have been proposed for HD, including excitotoxicity, oxidative stress, impaired energy metabolism, and
apoptosis. [10]
I. Exciting toxicity
Excitotoxicity refers to the neurotoxin effect of excitatory amino acids in the presence of excessive activation
of postsynaptic receptors. Intrastriatal injections of kainic acid, an agonist of a subtype of glutamate receptor,
produce lesions similar to those seen in HD. [11]
Intrastriatal injections of quinolinic acid, an N-methyl-D-aspartate (NMDA) receptor agonist, selectively affect
medium-sized GABA-ergic spiny projection neurons, sparing the striatal interneuron’s and closely mimicking
the neuropathology seen in HD. NMDA receptors are depleted in the striata of patients with HD, suggesting a
role of NMDA receptor-mediated excitotoxicity, but no correlation exists between the distribution of neuronal
loss and the density of such receptors.[5, 11] The theory that reduced uptake of glutamate by glial cells may
play a role in the pathogenesis of HD also has been proposed.
II. Oxidative stress
Oxidative stress is caused by the presence of free radicals (i.e., highly reactive oxygen derivatives) in large
amounts.[12] This may occur as a consequence of mitochondrial malfunction or excitotoxicity and can trigger
apoptosis. Striatal damage induced by quinolinic acid can be ameliorated by the administration of spin-trap
agents, which reduce oxidative stress,  providing indirect  evidence for the involvement of  free radicals in
excitotoxic cell death. [13]
III. Impaired energy metabolism
Impaired  energy metabolism  reduces  the  threshold  for  glutamate  toxicity  and can  lead  to  activation  of
excitotoxic mechanisms as well as increased production of reactive oxygen species.[8] Nuclear magnetic
resonance spectroscopy studies have shown elevated lactate levels in the basal ganglia and occipital cortex
of patients with HD.[12] Patients with HD have an elevated lactate-pyruvate ratio in the cerebrospinal fluid. A
reduction in the activity of the respiratory chain complex II and III (and less in complex IV) of mitochondria of
caudate neurons in patients with HD has been reported. [14]
 
Figure 3
The shrinkage of normal (left) and HD affected brain (right). [15]
The  genetic  basis  of  HD  is  the  expansion  of  a  cysteine-adenosine-guanine  (CAG)  repeat  encoding  a
polyglutamine tract in the N -terminus of the protein product called Huntingtin. The function of Huntington is
not known. Normally, it is located in the cytoplasm. [19, 20] The association of Huntingtin with the cytoplasmic
surface  of  a  variety  of  organelles,  including  transport  vesicles,  synaptic  vesicles,  microtubules,  and
mitochondria, raises the possibility of the occurrence of normal cellular interactions that might be relevant to
neuro-degeneration. N-terminal fragments of mutant Huntingtin accumulate and form inclusions in the cell
nucleus in the brains of patients with HD, as well as in various animal and cell models of HD. [18] The
presence of neuronal intra nuclear inclusions (NIIs) initially led to the view that they are toxic and, hence,
pathogenic.  More  recent  data  from  striatal  neuronal  cultures  transfected  with  mutant  Huntingtin  and
transgenic mice carrying the spinocerebellar at axia-1 (SCA-1) gene (another CAG repeat disorder) suggest
that NIIs may not be necessary or sufficient to cause neuronal cell death, but translocation into the nucleus is
sufficient  to  cause  neuronal  cell  death.Caspase  inhibition  in  clonal  striatal  cells  showed  no  correlation
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between the reduction of aggregates in the cells and increased survival. [19]
PATHOLOGY
The most striking pathology in HD occurs within the neostriatum, in which gross atrophy of  the caudate
nucleus and putamen is accompanied by selective neuronal loss and astrogliosis. Marked neuronal loss also
is seen in deep layers of the cerebral cortex. [16] Other regions, including the globuspallidus, thalamus, sub
thalamic  nucleus,  substantianigra,  and  cerebellum,  show varying  degrees  of  atrophy depending  on  the
pathologic grade. [17] The extent of gross striatal pathology, neuronal loss, and gliosis provides a basis for
grading the severity of HD pathology. No gross striatal atrophy is observed in grades 0 and 1. Grade 0 cases
have no detectable histologic neuropathology in the presence of a typical clinical picture and positive family
history  suggesting  HD.  [16,  17]  Grade  1  case  have  neuropathological  changes  that  can  be  detected
microscopically but without gross atrophy. In grade 2, striatal atrophy is present, but the caudate nucleus
remains convex. In grade 3, striatal atrophy is more severe, and the caudate nucleus is flat. In grade 4,
striatal atrophy is most severe, and the medial surface of the caudate nucleus is concave. [17, 18]
 
Figure 4
The figure of Huntington affected Brain. [18]
 
Figure 5
Comparison of Normal ion uptake to that of Huntington’s disease cell ion uptake. [14, 15, 19]
HUNTINGTIN
The Huntington’s disease is still not fully understood. What is known about Huntington’s disease is that it
occurs due to mutations in a single gene coding for a protein called Huntington. [20]Huntingtin is expressed in
all human and mammalian cells, with the highest concentrations in the brain and testes; moderate amounts
are present in the liver, heart, and lungs. [21] Recognizable autologous of protein is present in many species,
including zebra fish, drosophila, and slime moulds. The role of the wild-type protein is, yet, poorly understood,
as is the underlying pathogenesis of Huntington’s disease.[21, 22]One mechanism by which an autosomal-
110
African Journal of Neurological Sciences 2014 - Vol. 33, No 1
dominant disorder such as Huntington’s disease could cause illnesses by haploin sufficiency, in which the
genetic defect leads to inadequate production of a protein need for vital cell function.This idea seems unlikely
because terminal deletion or physical disruption of the HDgene in man does not cause Huntington’ disease.
[15, 16] Furthermore,  one copy of  the HDgene does not cause a disease phenotype in mice.  Whereas
homozygous absence of the HDgene is associated with embryonic lethality in animals, people homozygous
for the HDgene have typical development.Findings suggest that the mutant HDgene confers toxic gain of
function. [3, 4, 5] A persuasive line of evidence for this idea comes from nine other known human genetic
disorders  with  expanded  (and  expressed)  polyglutaminerepeats:  spinocerebellar  ataxia  types,
Dentatorubropallidoluysian atrophy, and spinobulbar muscular atrophy. For none of these disorders is there
evidence to suggest an important role for haplo insufficiency. [24]
In  spinobulbar  muscular  atrophy,  complete  deletion  of  the  androgen  receptor  is  not  associated  with
neuromuscular disease. All nine diseases show neuronal inclusions containing aggregates of polyglutamines
and all have a pattern of selective neuro-degeneration.One of the most striking features of these disorders is
the robust  inverse correlation between age of  onset  and number of  polyglutamine repeats.  [10] Results
suggest  that  the  length  of  the Polyglutamine  repeat  indicates  disease  severity irrespective  of  the gene
affected, with the longest repeat lengths associated with the most disabling early-onset (juvenile) forms of
these disorders. Although difficult to confirm, some data also suggest that the rate of progression might be
faster  with  longer  CAG  repeats,  particularly  for  individuals  with  juvenile-onset  disease.  [19]The  most
convincing evidence for a gain of function in Huntington’s disease is the structural biology of polyglutamine
strands. [10, 11]
This process needs a specific concentration of protein and a minimum of 37 consecutive glutamine residues,
follows a period of variable abeyance and proceeds faster with higher numbers of glutamine repeats. These
findings might account for both delayed onset of disease and the close correlation with polyglutamine length.
The rate of  aggregation increases with the number of  glutamine residues,  which accords with evidence
showing that length of expansion is associated with early age of onset. [2, 3, 10]
CLINICAL FINDINGS
Individuals with Huntington’s disease can become symptomatic at any time between the ages of 1 and 80
years; before then, they are healthy and have no detectable clinical abnormalities. [1, 5]This healthy period
merges  imperceptibly  with  a  pre-diagnostic  phase,  when  patients  show  subtle  changes  of  personality,
cognition,  and  motor  control.  Both  the  healthy  and  pre-diagnostic  stages  are  sometimes  called
presymptomatic, but in fact, the pre-diagnostic phase is associated with findings, even though patients can be
unaware of them. Diagnosis takes place when findings become sufficiently developed and specific. In the
pre-diagnostic phase, individuals might become irritable or disinherited and unreliable at work; multitasking
becomes  difficult  and  forgetfulness  in  addition,  anxiety  mounts.Family  members  note  restlessness  or
fidgeting, sometimes keeping their partners awake at night. [8, 31] Eventually, this stage merges with the
diagnostic  phase,  during  which  time  affected  individuals  show  distinct  chorea,  in  coordination,  motor
impersistence, and slowed saccadic eye movements.
Cognitive  dysfunction  in  Huntington’s  disease,  often  spares  long-term  memory  but  impairs  executive
functions, such as organizing, planning, checking, or adapting alternatives, and delays the acquisition of new
motor skills.  These features worsen over time; speech deteriorates faster than comprehension. [9]Unlike
cognition,  psychiatric  and  behavioral  symptoms  arise  with  some  frequency  but  do  not  show  stepwise
progression with disease severity. Depression is typical and suicide is estimated to be about five to ten times
that  of  the general  population (about 5-10%).  [4]  Manic  and psychotic  symptoms  can develop.  Suicidal
ideation is a frequent finding in patients with Huntington’s disease. In a cross-sectional study, about 9% of
asymptomatic at-risk individuals contemplated suicide at least occasionally, perhaps a result of being raised
by an affected parent and awareness of the disease. In the pre-diagnostic phase, the proportion rose to 22%,
but in patients who had been recently diagnosed, suicidal ideation was lower. The frequency increased again
in later stages of the illness. [6, 7]
The correlation of suicidal ideation with suicide has not been studied in people with Huntington’s disease, but
suicide attempts are not uncommon. In one study, researchers estimated that more than 25% of patients
attempt suicide at some point in their illness. Individuals without children might be at amplified risk, and for
these  people access  to  suicidal  means (i.e.,  drugs  or  weapons)  should  be restricted.  The  presence  of
affective symptoms, specific suicidal plans, or actions that increase isolation (e.g., divorce, giving away pets)
warrants similar  precautions.Although useful  for  diagnosis,  chorea is a poor marker  of  disease severity.
Patients with early onset Huntington’s disease might not develop chorea, or it might arise only transiently
during their illness. [1, 5]
JUVENILE HD
If the first symptoms and signs start before the age of 20 years, the disease is called Juvenile Huntington’s
disease (JHD).  Behaviors disturbances and learning difficulties at school are often the first  signs.  Motor
behavior is often hypokinetic and bradykinetic with dystonic components. Chorea is seldom seen in the first
decade and only appears in the second decade. Epileptic fits are frequently seen. The CAG repeat length is
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over 55 in most cases. In 75% of the juveniles the father is the affected parent. [21, 19] A complete and
accurate family history is invaluable in evaluating a child with symptoms suggestive of Huntington disease,
and can make the process of diagnosis much more straightforward. [22] However, there are situations in
which parents may not even be aware that HD is in the family; in other cases, an adopted child may be
involved. A number of tests may be used in conjunction with the presence or absence of a family history, and




Pictographically representation showing the inheritance nature of the disease
It is elucidated with example in the figure 6 that the dark colored animation is being affected and semi darks
are at risk and finally the light colored are not affected.
DIAGNOSIS
Diagnosis of HD is not easy andrequires an extensive care while diagnosing. The discovery of the HD gene in
1993 resulted in a direct genetic test to make or confirm a diagnosis of HD in an individual who is exhibiting
HD-like symptoms. Using a blood sample, the genetic test analyzes DNA for the HD mutation by counting the
number of repeats in the HD gene region. [11, 15]Pre-symptomatic testing is used for people who have a
family history of HD but have no symptoms themselves. The blood test confirms the presence or absence of
the HD mutation. It is encouraged that patients have either a blood sample from a family member who has
HD or  the results  of  his/her  genetic  test  for  confirming the diagnosis.  [31]  If  either  parent  had HD,  the
person’s chance would be 50-50.Prenatal testing is one of a range of options, which may be of interest to
couples who are at risk of passing the disease-causing version of the HD gene to a child. And also, chorionic
Villi Sampling is done to identify the presence of HD. In the past, no laboratory test could positively identify
people carrying the HD gene or those fated to develop HD before the onset of  symptoms.  [25] Usually
includes sessions devoted to genetic counseling, a neurological exam, a psychological interview, discussion
of  the  results,  and  follow-up.  Neurological  exam  is  meant  to  determine  whether  the  patient  has  any
symptoms, in which case they may choose to discontinue testing procedure.Sessions are meant to ensure
that the person about to undergo testing understands the implications of the knowledge of the results. A
neurologist will interview the individual intensively to obtain the medical history and rule out other conditions.
A tool used by physicians to diagnose HD is to take the family history, sometimes called a pedigree or
genealogy. [4, 5] It is extremely important for family members to be candid and truthful with a doctor who is
taking a family history.The doctor will also ask about recent intellectual or emotional problems, which may be
indications  of  HD,  will  test  the  person’s  hearing,  eye  movements,  strength,  coordination,  involuntary
movements (chorea), sensation, reflexes, balance, movement, and mental status, and will probably order a
number of laboratory tests as well. [4] People with HD commonly have impairments in the way the eye follows
or fixes on a moving target. Use medical imaging methods for diagnosis of the diseasesuch as Computerized
Tomography (CT), Magnetic Resonance Imaging (MRI), and Positron Emission Tomography (PET). [32]
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Figure 7
PET imaging of brain of HD affected patient with activation of microglial. [29]
Upon presence of contrast agent, the microglial cells in HD and normal brain are well assessed. Imaging
technologies allow investigators to view changes in the volume and structures of the brain and to pinpoint
when these changes occur in HD. Scientists know that in brains affected by HD, the basal ganglia, cortex,
and ventricles all show atrophy or other alterations. [20]
TREATMENT
There is no cure for Huntington’s disease, and there is no known way to stop the disease from getting worse.
The goal  of  treatment is  to slow down the symptoms and help the person function for  as long and as
comfortable as possible. [26, 30] Medications vary depending on the symptoms. Most common medications
as follows in table 1:










Beta-blockers (Atenolol, Propanol) 
Symptom: Antidepressants (depression, obsessive-compulsive behavior) 
Medications: 
Fluoxetine,  
Sertraline  hydrochloride,  
Nortriptyline 
Table 1 : Symptomatictreatmentregime [26-28, 30]
Table 1 is an overview of treatment options for HD. As there is no complete cure, a symptomatic treatment
regime is followed.
In August 2008, the U.S. Food and Drug Administration approved Tetrabenazine to treat chorea, making it
the first drug approved for use in the United States to treat the disease. [28]
In the year 2012, a clinical study is initiated on Zinc-finger nucleases (ZFNs) for treating HD. Zinc-finger
nucleases (ZFNs) are artificial restriction enzymesgenerated by fusing a zinc finger DNA-binding domain to a
DNA-cleavage domain. [33] Expanded CAG/CTG repeat tracts are the genetic basis for more than a dozen
inherited  neurological  disorders  including  Huntington’s  disease,  myotonic  dystrophy,  and  several
spinocerebellar ataxias. [20] It has been demonstrated in human cells that ZFNs can direct double-strand
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breaks (DSBs) to CAG repeats and shrink the repeat from long pathological lengths to short,  less toxic
lengths.
CONCLUSION
Several medications including baclofen, idebenone and vitamin E have been studied in clinical trials with
limited samples. More research work and clinical trials should be done to search effective drug molecules
that would provide a more rational approach in the treatment of Huntington’s disease. The more research
should  be aimed to develop therapeutic  agents that  alter  the course  of  neurodegenerative disease like
preventing neuronal death or stimulating neuronal recovery. As there is no specific cure for HD, the goal of
current  research is  to develop treatments that  can prevent,  retard or reverse neuronal cell  death. More
specific treatments for Huntington’s disease should become feasible.
Conflit d’intérêt : Aucun 
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